Navigation Links
Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
Date:10/24/2008

signed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by our partner, Forest Laboratories, solely for North American markets.

Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 50 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.

For further information please contact:

Novexel

Gordon Waldron, CFO

Tel: +33-1-5714-0777

gordon.waldron@novexel.com

Citigate Dewe Rogerson

Amber Bielecka/David Dible/Nina Enegren

Tel.: +44(0)207-638-95-71

amber.bielecka@citigatedr.co.uk


'/>"/>
SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
2. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
3. Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora
4. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
5. Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting
6. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
7. Cytopia Scientific Presentations on JAK2 Inhibitor Program
8. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
10. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
11. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... , - ... Supervision and Published* in November 2009, in the ... "Bone", Reveal new Benefits for,Peptan(TM) in Osteoporosis Prevention ... consumer concerns regarding long-term bone health,Rousselot has carried ... demonstrate,that an oral intake of Peptan(TM) may have ...
(Date:12/15/2009)... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... industry, today announced that it will release its fiscal ... after the market close. The Company will host a ... a.m. (Eastern Time) to discuss the results. ... call by dialing 1-888-324-9321 (Passcode: BLUD). Investors can also ...
(Date:12/15/2009)... BALTIMORE, Dec. 15 Champions Biotechnology, ... engaged in the development of advanced preclinical platforms ... of oncology drugs, today announced its financial results ... 2009. Full details of Company,s financial results ... www.championsbiotechnology.com . ,, Total revenues for the ...
Breaking Medicine Technology:Published in "Bone" Journal, Scientific Researches Confirm Peptan(TM) Hydrolyzed Collagen Benefits on Bone Health 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 5Nanogea Announces New Scientific Advisory Board Members 14402 1Nanogea Announces New Scientific Advisory Board Members 14402 2Nanogea Announces New Scientific Advisory Board Members 14402 3Breathe Safely LLC 3A Making Respirators 270 25 More Effective 59186 1Breathe Safely LLC 3A Making Respirators 270 25 More Effective 59186 2Chews 4 Health Dietary Supplements to be Featured on 26apos 3BBeauty Spaces 26apos 3B 59181 1Chews 4 Health Dietary Supplements to be Featured on 26apos 3BBeauty Spaces 26apos 3B 59181 2Chews 4 Health Dietary Supplements to be Featured on 26apos 3BBeauty Spaces 26apos 3B 59181 3
... Health, a,global provider of products and services that ... announced that it will now manufacture,compound and distribute ... The company,s new services for the clinical trial ... Medicine,s (SNM) 55th Annual Meeting,taking place in New ...
... American Society of Hypertension demonstrate that early blockade of angiotensin ... ... PARSIPPANY, N.J., June 16 A new study published in ... treatment olmesartan medoxomil was effective in reversing,the narrowing of the arteries ...
Other Medicine Technology:Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials 2New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 2New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 3New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 4New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 5New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 6New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 7New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 8New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 9
(Date:12/16/2009)... access to patient information could improve care, but ... 16 (HealthDay News) -- U.S. physicians support the ... exist about privacy problems, two new studies show. ... practice and specialist doctors in Massachusetts found that ... would improve patient quality of care, 70 percent ...
(Date:12/16/2009)... December 14, 2009) Unisense FertiliTech A/S has received a further 1.6 ... support of the EmbryoScope™ Embryo Monitoring System in order to meet ... was invested by LD Pensions and Unisense A/S that continue to ... ... Aarhus, Denmark (PRWEB) December 16, 2009 -- Unisense FertiliTech A/S has ...
(Date:12/16/2009)... time it takes to obtain a bachelor degree, an individual ... , ... (Vocus) December 16, 2009 ... Report Card on Higher Education" by the National Center for ... outpaced price increases in other sectors of the economy.”¹ Since ...
(Date:12/16/2009)... Help Hair Shake in all of the Florida Whole Foods store. ... ... Dr. Larry Shapiro, hair transplant and hair loss physician , is ... Help Hair Whey Protein Shake. Dr. Shapiro developed the all natural ... loss programs, working out and muscle building., , , , ,The Whole ...
(Date:12/15/2009)... State Authority, Ban on Annual Benefit Limits, & ... Consumer Watchdog condemned the removal of ... and the public option from the U.S. Senate ... the Senate must still make three essential fixes ... the entire health care system to the insurance ...
Breaking Medicine News(10 mins):Health News:Pros and Cons of Electronic Medical Records Weighed 2Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 2Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 3Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 4Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 5Health News:Florida Whole Foods Stores to Carry Dr. Lawrence Shapiro's Help Hair Shake 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5
... wide use in brass, bronze, die casting metal, ... nanoscale metal powders, because of their unique properties, ... such as dyes, paints, medical diagnosis, sunscreens and ... reactive catalyst in organic hydrogen reaction, automobile tail ...
... Bariatric surgery is a term derived from the Greek words: ... that either seal off most of the stomach to reduce// ... small intestine to reduce the calories the bodies can absorb. ... options available for treatment of obesity. ,Bariatric surgery ...
... the Bird Flu epidemic that is causing chaos in Turkey ... carrying the viral strain H5N1//. , ,The migratory ... were affected by the deadly virus strain H5N1 that can ... people due to the direct contact with affected and sick ...
... taken a major step forward in the war against cancer ... prostate cancer in animals//. ,The antibody that has been ... Dr. Robert E. Reiter, a professor of urology and researcher ... it tells the cancer that it is time to die. ...
... acute perinatal asphyxia remains an important cause of ... moderate encephalopathy have a 10% risk of death, ... of disabilities. 60% of infants with severe encephalopathy ... handicapped. ,Treatment is currently limited to supportive intensive ...
... are protesting against the introduction of genetically engineered rice ... on these genetically engineered rice//. The protests are collectively ... and agricultural sustainability civil societies are not happy with ... crops will have an adverse impact on the environment ...
Other Medicine News:Health News:Acute Toxicity Of Nano-Scale Zinc Powder: Severe Renal Damage And Anemia 2Health News:Changing Trends Regarding Insurance Cover For Weight Reduction Surgery 2Health News:Whole-body hypothermia reduces risk of death in Encephalopathy in infants 2Health News:Genetically modified rice faces strong protests in Asia 2
Bench Top Vertical Airflow Cabinets Production Protection...
... sealed isolation chamber provides a safe, ... sterile pharmaceuticals, in accord with USP-797 ... 100 (ISO 5) cleanliness conditions in ... IV rod and tilt-up front panel ...
... chemical fumes, allowing safe indoor ... filters remove most organic contaminants. ... flow speed = 100 fpm ... air speed monitor, quick-release filter/blower ...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
Medicine Products: